畜牧兽医学报 ›› 2017, Vol. 48 ›› Issue (2): 307-315.doi: 10.11843/j.issn.0366-6964.2017.02.014

• 预防兽医 • 上一篇    下一篇

微囊化大肠杆菌口服灭活疫苗对大鼠免疫效果的研究

夏瑞阳1,徐新龙1,2,董明娣1,陈俐静1,祁来芳1,王玲3,姚刚1*   

  1. (1.新疆农业大学动物医学学院,乌鲁木齐 830052;2.阿拉山口出入境检验检疫局,阿拉山口 833418;3.新疆合普联科检测技术研究院,乌鲁木齐 830019)
  • 收稿日期:2016-06-12 出版日期:2017-02-23 发布日期:2017-02-23
  • 通讯作者: 姚刚,男,博士生导师,教授,主要从事动物生长发育、畜产品质量安全研究,E-mail:yaogang516@163.com
  • 作者简介:夏瑞阳(1990-),女,新疆人,硕士生,主要从事基础兽医学研究。徐新龙对本文有相同贡献
  • 基金资助:

    新疆维吾尔自治区科技厅高技术项目(200911112);新疆农业大学研究生科研创新项目(XIAUGRI2015013);重点研发计划项目(2016YFD0500508)

Evaluation of the Immune Effect of Microencapsulated E. coli Inactivated Oral Vaccine in Rats

XIA Rui-yang1,XU Xin-long1,2,DONG Ming-di1,CHEN Li-jing1,QI Lai-fang1,WANG Ling3,YAO Gang1*   

  1. (1.College of Veterinary Medicine,Xinjiang Agricultural University,Urumqi 830052,China;2.Alashankou Entry-exit Inspection and Quarantine Bureau of the P.R.China,Alashankou 833418,China;3.Xinjiang Hope- Link Institute of Detection Technology,Urumqi 830019,China)
  • Received:2016-06-12 Online:2017-02-23 Published:2017-02-23

摘要:

不同血清型的致病性大肠杆菌是引起幼畜腹泻的主要病因之一。笔者拟对采用微囊包被技术制备的羊大肠杆菌灭活口服疫苗对大鼠的免疫效果进行评价。将制备的羊大肠杆菌蜂胶佐剂灭活苗作为芯材,天然高分子材料海藻酸钠为壁材,采用喷雾干燥法制备微囊化口服疫苗。微囊化口服疫苗的含菌量为7.52×1011菌•g-1。100只成年健康大鼠随机分为对照组、注射组和微囊包被口服疫苗组(再分为基础剂量、10倍基础剂量和20倍基础剂量三组),免疫后采用微量凝集试验和本室建立的间接ELISA方法检测免疫血清抗体效价并对细胞和黏膜免疫进行检测。微量凝集试验检测结果显示,免疫后7 d各试验组即可产生抗体,免疫后28 d时抗体效价达到高峰,随后开始下降。间接ELISA方法检测结果显示,免疫后14 d各试验组特异抗体转阳,并持续到28 d。口服组的抗体效价均显著高于对照组(P<0.05),而与注射组无差异(P >0.05),且各口服剂量组之间差异不显著(P>0.05)。免疫后35 d口服试验组特异抗体转为阴性,而注射组可维持到35 d;T淋巴细胞转化结果显示,免疫7 d后,三个口服剂量组的SI值均显著高于对照组和注射组(P<0.05)。免疫后口服各剂量组的肠黏膜分泌型免疫球蛋白A(sIgA)含量均高于同期的对照组和注射组,21 d后sIgA含量达到高峰。微囊包被口服疫苗能够产生与注射组同样的体液免疫,同时还可以刺激大鼠机体产生较好的细胞免疫和黏膜免疫。

关键词: 大肠杆菌, 口服疫苗, 微囊包被, 免疫, 大鼠

Abstract:

The pathogenic E. coli of different serotypes is a major sort of the causative agents of the diarrhea of young animals. In the present study a microencapsulated E. coli inactivated oral vaccine was prepared and its immune effect in rats was evaluated. The prepared ovine pathogenic E. coli inactivated vaccine with propolis-adjuvant as the core material was microencapsulated by natural alginate polymer as wall material, in which 7.52×1011 bacteria•g-1 dry powder were encapsulated. A hundred Wistar rats were divided into randomly 3 groups, i.e., the control, injection immunization and oral immunization groups, in which the oral immunization group was futher-divided in to the basal dose, 10-fold dose and 20-fold dose groups. After the inoculation the specific antibody was tested by the micro-agglutination test and the indirect ELISA, and the cellular immunity and mucosal IgA were detected. The micro-agglutination test showed that the specific antibody was produced from day 7 after the inoculation and reached to the peak at day 28, then declined thereafter. The indirect ELISA test showed that the antibody was positive from day 14 to day 28 after inoculation. The antibody titers in oral vaccine groups were significantly higher than that in the control (P<0.05), but not in the injection group (P>0.05), and were not significantly between the oral vaccine groups (P>0.05). The antibody titers in the oral vaccine groups declined to negative level at day 35 after inoculation whereas the injection group remained to be antibody-positive;T lymphocyte transformation test showed that SI index in 3 oral vaccine groups was higher than that in the control or the injection group significantly (P<0.05). The sIgA levels in oral vaccine groups were also significantly higher that either in the control or injection group, reaching to the peak at day 21 after inoculation. These data suggest that microencapsulated E. coli inactivated oral vaccine could produce the humoral immunity equivalent to the injected vaccine but with better cell and mucosal immunity in rats.

Key words: Escherichia coli, oral vaccine, microcapsule coating, immunization, rat

中图分类号: